Klinikum Chemnitz

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning (2023) Eckardt JN, Röllig C, Metzeler K, Kramer M, Stasik S, Georgi JA, Heisig P, et al. Journal article Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia A Randomized Clinical Trial (2023) Bornhaeuser M, Schliemann C, Schetelig J, Roellig C, Kramer M, Glass B, Platzbecker U, et al. Journal article Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia (2023) Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, et al. Journal article Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification (2023) Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, et al. Journal article Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience (2023) Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Journal article Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 (2023) Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, et al. Journal article Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, et al. Conference contribution Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis (2022) Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Schaefer-Eckart K, Steffen B, et al. Conference contribution Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (2022) Georgi JA, Stasik S, Zukunft S, Hartwig M, Roellig C, Oelschlaegel U, Krug U, et al. Conference contribution Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution